Pharming Group NV (PHARM) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.121x

Based on the latest financial reports, Pharming Group NV (PHARM) has a cash flow conversion efficiency ratio of 0.121x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€32.03 Million ≈ $37.44 Million USD) by net assets (€264.64 Million ≈ $309.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PHARM defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Pharming Group NV - Cash Flow Conversion Efficiency Trend (2005–2024)

This chart illustrates how Pharming Group NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Pharming Group NV Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pharming Group NV ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Tian Jin Motor Dies Co Ltd SHE:002510	0.053x
Zhejiang Hailide New Material Co Ltd SHE:002206	0.065x
EcoRodovias Infraestrutura e Logística S.A SA:ECOR3	0.312x
Sinoseal Holding Co Ltd SHE:300470	0.035x
Matrix Design Co. Ltd. A SHE:301365	N/A
Shanghai Runda Med Tech Co SHG:603108	0.027x
Yunnan Hongxiang Yixintang SHE:002727	0.069x
Lotte Tour Dev KO:032350	-0.024x

Annual Cash Flow Conversion Efficiency for Pharming Group NV (2005–2024)

The table below shows the annual cash flow conversion efficiency of Pharming Group NV from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see PHARM market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€214.16 Million ≈ $250.38 Million	€-1.79 Million ≈ $-2.10 Million	-0.008x	+91.51%
2023-12-31	€198.05 Million ≈ $231.55 Million	€-19.55 Million ≈ $-22.85 Million	-0.099x	-188.20%
2022-12-31	€204.64 Million ≈ $239.24 Million	€22.90 Million ≈ $26.77 Million	0.112x	-40.31%
2021-12-31	€192.72 Million ≈ $225.31 Million	€36.13 Million ≈ $42.23 Million	0.187x	-62.14%
2020-12-31	€183.73 Million ≈ $214.80 Million	€90.98 Million ≈ $106.36 Million	0.495x	-22.12%
2019-12-31	€117.26 Million ≈ $137.09 Million	€74.56 Million ≈ $87.16 Million	0.636x	-2.76%
2018-12-31	€70.64 Million ≈ $82.58 Million	€46.19 Million ≈ $54.00 Million	0.654x	-67.83%
2017-12-31	€22.56 Million ≈ $26.37 Million	€45.84 Million ≈ $53.60 Million	2.032x	+658.01%
2016-12-31	€28.89 Million ≈ $33.77 Million	€-10.52 Million ≈ $-12.30 Million	-0.364x	+47.13%
2015-12-31	€26.06 Million ≈ $30.47 Million	€-17.95 Million ≈ $-20.99 Million	-0.689x	-289.43%
2014-12-31	€36.29 Million ≈ $42.43 Million	€-6.42 Million ≈ $-7.50 Million	-0.177x	+89.31%
2013-12-31	€6.92 Million ≈ $8.09 Million	€-11.45 Million ≈ $-13.39 Million	-1.655x	-223.33%
2012-12-31	€-10.12 Million ≈ $-11.83 Million	€-13.58 Million ≈ $-15.88 Million	1.342x	-89.84%
2011-12-31	€-1.54 Million ≈ $-1.80 Million	€-20.34 Million ≈ $-23.78 Million	13.210x	+2676.91%
2010-12-31	€13.43 Million ≈ $15.70 Million	€-6.89 Million ≈ $-8.05 Million	-0.513x	+64.11%
2009-12-31	€19.07 Million ≈ $22.30 Million	€-27.24 Million ≈ $-31.85 Million	-1.428x	-75.31%
2008-12-31	€17.45 Million ≈ $20.40 Million	€-14.21 Million ≈ $-16.62 Million	-0.815x	-30.04%
2007-12-31	€50.58 Million ≈ $59.13 Million	€-31.69 Million ≈ $-37.05 Million	-0.626x	-59.15%
2006-12-31	€65.78 Million ≈ $76.91 Million	€-25.89 Million ≈ $-30.27 Million	-0.394x	+12.20%
2005-12-31	€34.04 Million ≈ $39.79 Million	€-15.26 Million ≈ $-17.84 Million	-0.448x	--

About Pharming Group NV

AS:PHARM Netherlands Biotechnology

Market Cap

$917.94 Million

€785.17 Million EUR

Market Cap Rank

#9440 Global

#55 in Netherlands

Share Price

€1.13

Change (1 day)

-0.04%

52-Week Range

€0.84 - €1.78

All Time High

€1.78